These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30958721)

  • 1. Generalizability and Implications of the H
    Segar MW; Patel KV; Berry JD; Grodin JL; Pandey A
    Circulation; 2019 Apr; 139(15):1851-1853. PubMed ID: 30958721
    [No Abstract]   [Full Text] [Related]  

  • 2. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Zhu W; Wu Y; Zhou Y; Liang W; Xue R; Wu Z; Dong Y; Liu C
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):763-772. PubMed ID: 32583288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H2FPEF Score as a Prognostic Value in HFpEF Patients.
    Sueta D; Yamamoto E; Nishihara T; Tokitsu T; Fujisue K; Oike F; Takae M; Usuku H; Takashio S; Arima Y; Suzuki S; Nakamura T; Ito M; Kanazawa H; Sakamoto K; Kaikita K; Tsujita K
    Am J Hypertens; 2019 Oct; 32(11):1082-1090. PubMed ID: 31271191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
    Onarecker C
    J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy.
    Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P
    Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
    Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
    J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Minamisawa M; Claggett B; Suzuki K; Hegde SM; Shah AM; Desai AS; Lewis EF; Shah SJ; Sweitzer NK; Fang JC; Anand IS; O'Meara E; Rouleau JL; Pitt B; Pfeffer MA; Solomon SD; Vardeny O
    Circ Heart Fail; 2021 Nov; 14(11):e008293. PubMed ID: 34674539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the H
    Myhre PL; Vaduganathan M; Claggett BL; Lam CSP; Desai AS; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Shah AM; Lewis EF; Rouleau J; Pitt B; Solomon SD
    Eur J Heart Fail; 2019 Oct; 21(10):1288-1291. PubMed ID: 31332920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
    Reddy YNV; Carter RE; Obokata M; Redfield MM; Borlaug BA
    Circulation; 2018 Aug; 138(9):861-870. PubMed ID: 29792299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone, fibrosis and heart failure with preserved ejection fraction.
    Reddy YNV; Sundaram V
    Eur J Heart Fail; 2022 Sep; 24(9):1569-1572. PubMed ID: 35851716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.